Summary Abstract Clopidogrel (Plavix®, Iscover®) selectively and irreversibly inhibits
adenosine diphosphate (ADP)-induced platelet aggregation. Long-term administration of …

Antiplatelet therapy plays a pivotal role in the treatment of patients across the entire
spectrum of coronary artery disease. Platelets are believed to be integrally involved in both …

The question of the use of antiplatelet medications is front page news nowadays, for various
reasons. Apart from the purely scientific dimensions, other aspects have received much …

Ischemic heart disease (IHD) represents a pathophysiologic continuum consisting of stable
angina, unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment …

Clopidogrel has demonstrated improved outcomes for patients with acute coronary
syndromes in several large randomized controlled trials. However, some questions exist …

Background: Numerous randomized studies have shown that the combination of clopidogrel
with aspirin yields better clinical outcomes than monotherapy in patients with acute vascular …

Background Despite improvements in the emergency treatment of myocardial infarction (MI),
early mortality and morbidity remain high. The antiplatelet agent clopidogrel adds to the …

Background It remains unclear whether clopidogrel is better suited than aspirin as the long-
term antiplatelet monotherapy following dual antiplatelet therapy (DAPT) after percutaneous …

Clopidogrel has been evaluated across the spectrum of secondary and primary prevention.
Initially, the CAPRIE trial randomized patients with recent myocardial infarction, ischemic …

BACKGROUND: Clopidogrel is a more potent antiplatelet agent than aspirin, resulting in
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …